NYSE · Healthcare
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
As-reported financials and recent SEC filings for TEVA PHARMACEUTICAL INDUSTRIES LTD, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$17.26B
Net income
$1.41B
Net margin
8.2%
Diluted EPS
$1.21
ROE
17.8%
P/E (TTM)
24.8×
Market cap
$38.67B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B |
| Gross profit | $8.94B | $8.06B | $7.65B | $6.97B | $7.59B |
| Operating income | $2.16B | $-303.0M | $433.0M | $-2.20B | $1.72B |
| Net income | $1.41B | $-1.64B | $-559.0M | $-2.45B | $417.0M |
| Diluted EPS | $1.21 | $-1.45 | $-0.50 | $-2.20 | $0.38 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →1442026-06-18
View on EDGAR →42026-06-16
View on EDGAR →1442026-06-11
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →Go deeper on TEVA
Search TEVA PHARMACEUTICAL INDUSTRIES LTD’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.